Project Grant R41AI170413
Award Date 7/14/22
Completion Date 6/30/23
Dollars Obligated $600K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $314,363 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Biotherapeutics, Inc., a clinical-stage biotechnology company in Blacksburg, Virginia. The funding will support the development of a novel oral small molecule therapeutic for the treatment of systemic lupus erythematosus (SLE), an autoimmune disease affecting 1.5 million Americans. The company has identified a novel...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $149,008 Cooperative Agreement under the Trans-NIH Research Support program (CFDA 93.310) to Cartesian Therapeutics Inc. to develop and evaluate a novel cell therapy for the treatment of systemic lupus erythematosus (SLE). The funding will support a Phase 2A clinical trial and the design of a subsequent randomized, placebo-controlled Phase 2B trial to test "Descartes-08", an RNA-engineered chimeric antigen...
- This Project Grant award for $684,206, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop a nanoparticle-based immunotherapy to address the complex immune dysregulation associated with sepsis. The funds will support research to advance the development of "immunomodulatory nanoparticles" (INPs) - a drug-free class of poly(lactic acid)-based nanoparticles designed to...
- This $256,808 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to better define the molecular mechanisms that cause and perpetuate systemic lupus erythematosus (SLE). The University of Washington is conducting this research, which focuses on analyzing altered mRNA splicing in SLE neutrophils and exploring the consequences of these splicing changes, including...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $392,714 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Cornell University to develop lipid nanoparticles (LNPs) for improving endosomal escape and reducing reactogenicity of nucleic acid-based therapies. The research aims to enhance the cytoplasmic release and reduce inflammatory responses of LNPs through novel ionizable lipid designs, including pH-switchable pyridine...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $300,000 Project Grant under the Allergy and Infectious Diseases Research (CFDA 93.855) program to Optimeos Life Sciences, Inc., a biotechnology company in New Jersey. The grant supports the development of an off-the-shelf nanoparticle platform for in vivo stem cell gene therapy to treat severe immune deficiencies such as ADA-SCID. The project aims to deliver a DNA payload in nanoparticles targeting hematopoietic stem...
- This federal Project Grant award of $350,000 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop polymer-derived biomaterials for messenger RNA (mRNA) delivery to induce antigen-specific immune tolerance. The award supports research to evaluate diverse nanocarrier formulations encapsulating antigens and mRNAs encoding tolerogenic proteins, investigate the biodistribution and...
- This Project Grant, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), is supporting the development of a novel, targeted small molecule inhibitor of the nucleoside salvage pathway to treat systemic lupus erythematosus (SLE). The total funding amount is $994,978, with the award period running from Aug 7, 2025 to Jul 31, 2028. The awardee, Trethera Corp, is a clinical-stage...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,000,000 Project Grant to Partillion Bioscience Corp, a biotechnology company based in Los Angeles, California. The grant, funded under NIAID's Allergy and Infectious Diseases Research program (CFDA 93.855), supports the development of advanced workflows utilizing Partillion's specialized hydrogel microparticle technology called "nanovials". The goal is to enable ultra high-throughput screening and functional...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to determine the therapeutic potential of CpG-B oligonucleotides (ODNs) for the management of systemic lupus erythematosus (SLE). The $132,930 award, active from January 2025 to July 2028, will support in vitro and in vivo studies using MRL/lpr and humanized mouse models to investigate how CpG-B ODNs, which mimic bacterial...